Organon & Co. (OGN) has a MoatMap StockRank of 100/100 based on Quality (61/100), Value (61/100), and Momentum (89/100) factor scores. The current signal is STRONG BUY. Organon operates in the healthcare sector, which generally benefits from stable demand. However, the 'Un' country designation prevents any meaningful assessment of specific macro tailwinds, capital flows, or geopolitical exposure that would create an asymmetric opportunity as per the Druckenmiller lens. While healthcare can be resilient, there's no clear thesis for a powerful, unpriced macro tailwind.
Organon & Co. is a global healthcare company dedicated to improving women's health and offering a portfolio of established brands across various therapeutic areas, alongside a growing biosimilars pipeline. Its competitive edge lies in a focused strategy on underserved women's health needs, leveraging a strong portfolio of trusted, established products with significant market presence globally.
| Price | $13.43 |
| Market Cap | $3.5B |
| P/E (TTM) | 14.43 |
| P/E (Forward) | 3.67 |
| Price/Book | 3.90 |
| Return on Equity | 34.0% |
| Return on Invested Capital | 8.9% |
| Debt/Equity | 948.95 |
| Gross Margin | 53.8% |
| Operating Margin | 18.7% |
| Revenue Growth | -3.5% |
| Dividend Yield | 0.6% |
| Free Cash Flow | $529M |
Organon & Co. operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).